10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Levocabastine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Levocabastine

Levocabastine

Class : B

Show all info

Print

Contact us

  1. Olsson P, Berglind N, Bellander T, Stjärne P. Prevalence of self-reported allergic and non-allergic rhinitis symptoms in Stockholm: relation to age, gender, olfactory sense and smoking. Acta Otolaryngol. 2003;123(1):75-80.

  2. Matheson MC, Dharmage SC, Abramson MJ, Walters EH, Sunyer J, de Marco R et al. Early-life risk factors and incidence of rhinitis: results from the European Community Respiratory Health Study--an international population-based cohort study. J Allergy Clin Immunol. 2011;128(4):816-823e5.

  3. Livostin (levocabastine) nasal spray. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-11-24, cited 2022-08-04]

  4. Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R. The pharmacokinetic properties of topical levocabastine A review. Clin Pharmacokinet. 1995;29(4):221-30.

  5. Livostin (levocabastine) eye-drops. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-10-16, cited 2022-08-04]

  6. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Olsson P, Berglind N, Bellander T, Stjärne P. Prevalence of self-reported allergic and non-allergic rhinitis symptoms in Stockholm: relation to age, gender, olfactory sense and smoking. Acta Otolaryngol. 2003;123(1):75-80.
  2. Matheson MC, Dharmage SC, Abramson MJ, Walters EH, Sunyer J, de Marco R et al. Early-life risk factors and incidence of rhinitis: results from the European Community Respiratory Health Study--an international population-based cohort study. J Allergy Clin Immunol. 2011;128(4):816-823e5.
  3. Livostin (levocabastine) nasal spray. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-11-24, cited 2022-08-04]
  4. Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R. The pharmacokinetic properties of topical levocabastine A review. Clin Pharmacokinet. 1995;29(4):221-30.
  5. Livostin (levocabastine) eye-drops. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-10-16, cited 2022-08-04]
  6. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]